Loading...
•
Dec 31, 2020
Supernus Q4 2020 Earnings Report
Reported record revenues and operating earnings based on the growth of Trokendi XR and Oxtellar XR and the addition of the CNS products acquired during the year.
Key Takeaways
Supernus Pharmaceuticals reported Q4 2020 net product sales of $140.7 million, a 44% increase compared to the same period in 2019. The company's full year 2020 total revenues were $520.4 million, a 32% increase compared to 2019. Supernus is preparing for the expected launch of SPN-812 in the second quarter of 2021.
Fourth quarter net product sales increased by 44% year-over-year, reaching $140.7 million.
The increase in net product sales was driven by the addition of $39.5 million from acquired commercial products and $3.3 million from Trokendi XR and Oxtellar XR.
Operating earnings for the fourth quarter were $43.0 million, compared to $40.8 million in the fourth quarter of 2019.
The company had $772.9 million in cash, cash equivalents, and marketable securities as of December 31, 2020.
Revenue by Segment
Forward Guidance
The Company expects to achieve total revenues between $550 million and $580 million in 2021. Combined R&D and SG&A expenses are expected to be between $380 million and $410 million. Operating earnings are expected to be between $65 million and $90 million.
Positive Outlook
- Total revenues are expected to be between $550 million and $580 million.
- SPN-812 net product sales are expected to be $10 million.
- Operating earnings are expected to be between $65 million and $90 million.
- Amortization of intangible assets is expected to be $24 million.
Challenges Ahead
- Combined R&D and SG&A expenses are expected to be between $380 million and $410 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...